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Abstract Autism Spectrum Disorder (ASD) is a pervasive
neurodevelopmental condition characterized by variable
impairments in communication and social interaction as
well as restricted interests and repetitive behaviors.
Heterogeneity of presentation is a hallmark. Investigations
of immune system problems in ASD, including aberrations
in cytokine profiles and signaling, have been increasing in
recent times and are the subject of ongoing interest. With
the aim of establishing whether cytokines have utility as
potential biomarkers that may define a subgroup of ASD,
or function as an objective measure of response to treat-
ment, this review summarizes the role of the immune
system, discusses the relationship between the immune
system, the brain, and behavior, and presents previously-
identified immune system abnormalities in ASD, specifi-
cally addressing the role of cytokines in these aberrations.
The roles and identification of biomarkers are also
addressed, particularly with respect to cytokine profiles in
ASD.
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Introduction
Autism Spectrum Disorders (ASDs) are complex, pervasive
neurodevelopmental conditions with a largely unknown
etiology and a significant male bias. ASDs are behaviorally
defined and characterized by deficits in social communi-
cation and interaction, and the presence of restricted,
repetitive patterns of behavior, interests, or activities [1].
Developmental trajectories and patterns of severity vary
substantially, with all facets of daily functioning potentially
impacted. The vast clinical heterogeneity is a hallmark.
Comorbid psychiatric and medical conditions are frequently
reported, including social anxiety disorder, attention deficit
disorder, immune system abnormalities, gastrointestinal
disorders, mitochondrial dysfunction, sleep disorders, and
epilepsy [2–6]. The multifaceted nature of the condition has
resulted in investigations aiming to characterize biological
subtypes of ASD. However, an understanding of the bio-
logical mechanisms driving pathophysiology is evolving.
Immune system aberrations, including altered cytokine
profiles, are believed to have a role in ASD [7, 8]. Accu-
mulating evidence of alterations in central and peripheral
immune system functioning supports the proposal that there
is a subgroup of individuals with ASD who have some form
of immune system dysregulation [9]. Altered cytokine
levels may facilitate the identification of ASD subtypes as
well as provide biological markers of the response to
effective treatments.
The Immune System
The immune system is a complicated group of defense
mechanisms that are triggered in order to protect an
organism from disease- or illness-causing pathogens,
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which include bacteria, viruses, fungi, and parasites. An
antigen, considered foreign by the host’s body, is a mole-
cule that stimulates the immune system to produce anti-
bodies which function to identify and neutralize or remove
the antigen. Many interconnected organs, molecules, cells,
and pathways play roles in a fully functional immune
system, which is comprised of two interconnected systems
of immunity: innate and adaptive [10]. These two systems
work together to protect the body from pathogens.
Innate immunity refers to first-line defense mechanisms
that respond to an infection immediately or within hours of
the host being attacked by a pathogen. The innate immune
response relies on physical barriers, such as the epithelial
layers of the skin and mucosal and glandular tissue surfaces
connected to the body’s openings, as well as chemical
barriers, which include soluble antimicrobial proteins and
peptides, and an acidic pH. When pathogens breach these
barriers, cellular innate immune responses are triggered
through a pathogen-recognition process involving an array
of cells with cell surface and intracellular receptors. Groups
of pathogens present with characteristic pathogen-associ-
ated molecular patterns, which are recognized by pattern
recognition receptors expressed by many different immune
cells [11]. Some cells are activated to phagocytose and
degrade the pathogen, a process through which macro-
phages and neutrophils engulf and destroy extracellular
microbes. Cell receptors can also be activated, causing the
cells to produce antimicrobial substances that eliminate the
pathogens. Other cellular activation processes lead to the
production of cytokines and chemokines, which are pro-
teins that recruit cells, molecules, and fluid to sites of
infection. This procedure results in the physiological
changes known as inflammation [10]. Other effectors of
innate immunity are natural killer (NK) cells that, through
cytokine production or cytotoxicity, contain infections until
an adaptive immune response is initiated.
When innate immunity is insufficient, for example when
features of certain pathogens allow them to evade the
defense mechanisms of the innate immune system, the
adaptive immune response is activated. The adaptive
response is initiated a few days after initial exposure to the
pathogen and breach of the physical or chemical barriers.
This response is more comprehensive and antigen-specific
than the innate response. The adaptive immune system is
able to recognize, eliminate, and remember pathogens. The
innate immune system is not considered to have this
memory component. However, demonstrations of NK cell
memory in viral infections indicate that these cells have
attributes of both innate and adaptive immunity [12]. There
are two types of adaptive immune response, both carried
out by lymphocytes. The first type of response is an anti-
body response carried out by B lymphocytes, or B cells,
which, when activated by an antigen, secrete antibodies,
also known as immunoglobulins. B cells are formed in the
bone marrow. The second type of adaptive immune
response is a cell-mediated immune response where acti-
vated T cells specifically recognize and neutralize or
eliminate antigens. T cells mature in the thymus, which is a
lymphoid organ of the immune system. Residual B and T
cells remaining after antigen exposure function as memory
cells that are activated by subsequent pathogen challenges.
The innate and adaptive immune responses discussed
above are characteristic of a regulated immune system
contributing to the maintenance of homeostasis and pre-
venting disruptions of normal functions of the body. A
regulated immune system requires an optimal balance of
pro- and anti-inflammatory signaling. Inflammation may
not be a problem in isolation, but if an unregulated or
dysregulated immune system responds to physiological
changes initiated by pathogens, then the inflammation may
be problematic. An aberrant immune system may manifest
as upregulation of the inflammatory/immune response or as
immune deficiency compromising host defense. Allergies,
asthma, and autoimmune disorders are all conditions
associated with immune dysfunction.
Cytokines and the Immune System
Cytokines are cell-signaling molecules that facilitate
communication among cells of both the innate and adaptive
immune systems. They are primary regulators of inflam-
mation, coordinating the response to infection and associ-
ated immune challenges and are involved in a multitude of
biological processes. As part of an integrated network,
cytokines stimulate and modulate immune system activity
and induce their own synthesis and the synthesis of other
cytokines. They are typically soluble molecules although
some remain cell-bound. Cytokines can be broadly classi-
fied into three groups based on the type of immune
response: adaptive immunity, pro-inflammatory signaling,
and anti-inflammatory signaling [13]. Chemokines are a
subpopulation of cytokines that initiate the recruitment of
well-defined leukocyte subsets through chemical stimuli
[14]. Cells attracted to the chemokine follow a signal of
increasing concentration towards the source of the che-
mokine, usually an infected or damaged cell. As cell sig-
naling molecules, cytokines bind to receptors on the plasma
membrane and elicit effects through the activation of an
intracellular signaling cascade. Cytokines can be further
classified based on the distance between the cell secreting
the signaling ligand and the cell receiving the chemical
signal [10]. Endocrine action is when cytokines pass
through the bloodstream before reaching the target.
Cytokines that act near the secreting cell are paracrine.
Autocrine action is when cells can secrete a signal that is
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received through its own receptors. Cytokines have been
characterized as belonging to one of six groups based on
cytokine and cytokine receptor structure, but members may
exhibit diverse functionality. The cytokine families and
some of the members of each group are detailed in Table 1
[10].
T and B lymphocytes mediate adaptive immunity.
However, it is the T helper cells that are required for almost
all adaptive immune responses [15]. They help activate B
cells to secrete antibodies and macrophages to eliminate
pathogens. Naı¨ve T helper cells are differentiated into
functional types defined by their pattern of cytokine pro-
duction and function: Type 1 T helper (Th1), Type 2 T
helper (Th2), T-regulator, and Th17 cells [16]. Prolifera-
tion and differentiation are functions of the particular
cytokine milieu and signaling requirements during T cell
receptor activation. Differentiation into either Th1 or Th2
effector cells then determines the nature of the subsequent
adaptive immune responses activated by effector cells [17].
Th1 cells produce interferon (IFN)-c, their signature
cytokine and interleukin (IL)-2, while many also produce
tumor necrosis factor (TNF)-a. Th2 signature cytokines are
IL-4, IL-5, and IL-13, but these cells also make TNF-a, and
some produce IL-9 and modest amounts of IL-2 [16].
Immune regulation is thought to require homeostasis
between Th1 and Th2 activity [15]. If either Th1 or Th2
dominates, then the other response may be suppressed.
Lower proportions of Th1 cells and higher proportions of
Th2 cells have been found in children with ASD compared
to healthy controls, providing evidence of an imbalance of
Th1- and Th2-like cytokines in ASD [18]. In addition,
analysis of peripheral blood mononuclear cells from chil-
dren with ASD showed increased activation of both the
Th1 and Th2 arms of the adaptive immune response, with a
Th2 dominance and no compensatory increase in expres-
sion of the regulatory cytokine IL-10 [19].
Each cytokine can be produced by a single cell type or
multiple cell types. For example, Th1 cells produce IFN-c,
IL-2, and TNF-b, while Th2 cells produce IL-4, IL-5, IL-6,
IL-9, and IL-10 [20]. However, granulocyte macrophage
colony-stimulating factor (GM-CSF) can be produced by
multiple cell types, including macrophages, endothelial
cells, and fibroblasts [21]. Similarly, IFN-b can be pro-
duced by multiple cell types including fibroblasts and
epithelial cells. Cytokines can act on a single or multiple
cell types. For example, IL-12 acts on Th1 cells, while IL-1
acts on T cells, B cells, macrophages, endothelial cells,
fibroblasts, and epithelial cells, and all interferons act on
multiple cell types. Cytokines also exhibit redundancy,
meaning multiple cytokines exert the same biological
Table 1 Details of six cytokine families and examples of family members.
Cytokine Family Examples Characteristics
Interleukin 1 family IL-1a, IL-b, IL-RA Induce responses against infection that are primarily pro-
inflammatory
IL-RA antagonizes effects of IL-1a and IL-b
Hematopoietin (Class
I cytokine) family
IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-12p40, IL-12p70,
IL-13, IL-15, IL-23, GM-CSF, G-CSF
Largest family of cytokines, all members sharing a 4-helix
bundle structure
Sequence and functional diversity




IFN-c, IL-10 Mediate early antiviral responses
Activate macrophages, interact with cells of the adaptive
immune system, and support the generation of Th1 cells
Tumor necrosis factor
family
TNF-a, TNF-b1 Expressed in either soluble or membrane-bound form
Cause apoptosis
Interleukin 17 family IL-17 Primarily pro-inflammatory
Chemokine family IL-8, Eotaxin, IP-10 (CXCL10), MCP-1(CCL2), MIP-
1a (CCL3), MIP-1b (CCL4), RANTES (CCL5)
Secondary pro-inflammatory mediators
Stimulate recruitment of well-defined leukocyte subsets
Promote chemoattraction, movement of immune system cells
into, within, and out of lymphoid organs
CCL, chemokine (C-C motif) ligand; CXCL, chemokine (C-X-C) ligand; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte
macrophage colony-stimulating factor; IFN-c, interferon-c; IL, interleukin; IL.1RA, IL-1 receptor antagonist; IP-10, IFNc-inducible protein 10;
MCP-1, monocyte chemotactic protein-1; MIP-1a, macrophage inflammatory protein-1a; MIP-1b, macrophage inflammatory protein-1b;
RANTES, regulated on activation, normal T cell expressed and secreted; Th, T helper; TNF-a, tumor necrosis factor-a.
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action. Furthermore, an individual cytokine can have
multiple effects on a target cell. IFN-c induces antiviral
proteins, upregulates major histocompatibility complex
Class I antigens, stimulates NK and IL-12 production, and
induces antiproliferative effects [22]. Increased levels of
IFN-c and IL-12 can induce inflammation whereas
increased levels of transforming growth factor (TGF)-b,
IL-4, and IL-10 can downregulate inflammation [23]. The
classification of the biological action of cytokines as either
pro-inflammatory or anti-inflammatory may be dependent
on the amount of cytokine, the nature of the target cell, the
nature of the activating signal, the nature of produced
cytokines, and the timing and sequence of cytokine action
[24].
The Immune System, the Nervous System,
Behavior, and the Role of Cytokines
The immune system and the nervous system are intricately
interconnected. The functional status of the immune system
affects a multitude of biological processes, including brain
function and development, which can be affected when the
innate and adaptive immune responses are dysregulated
[25]. Sickness behavior, a term used to describe changes in
the subjective experience and behavior occurring in a
physically ill person [26], provides an example of how,
through multiple mechanisms, the immune system can
influence brain function and subsequent behavior [25].
Nonspecific symptoms of sickness behavior include fever,
nausea, reduced appetite, fatigue, irritability, and with-
drawal from physical and social environments [27]. Sick-
ness behavior is considered an organized and evolved
strategy to facilitate the role of fever in fighting infection. It
is initiated by pro-inflammatory cytokines that are pro-
duced at the site of infection by activated accessory
immune cells and is characterized by endocrine, auto-
nomic, and behavioral changes [27]. The brain recognizes
cytokines such as the pro-inflammatory cytokines IL-1a,
IL-1b, TNF-a, and IL-6 as molecular signals of sickness
[28]. Furthermore, TNF-a, IL-6, and IL-1b can cross the
blood-brain barrier and act on the hypothalamus where
they promote fever and sickness behavior [29]. The simi-
larities of symptom expression in sickness behavior and
depression have led to the hypothesis that cytokines and
inflammatory factors are involved in the pathophysiology
of neuropsychiatric disorders, and this has been a catalyst
for extensive research into the pathways and mechanisms
through which the immune system influences the brain and
behavior [30]. Interestingly, another example of a rela-
tionship between symptom and cytokine expression
involves immunotherapy in cancer patients, in whom pro-
longed exposure to the proinflammatory cytokine IL-2
results in dose- and time-related cognitive dysfunction and
altered behavior [31].
The literature identifying abnormal cytokine profiles in
depression, bipolar disorder, and schizophrenia [32–34]
collectively suggests that cytokines induce both sickness
behavior and neuropsychiatric symptoms, and that
inflammation is a key pivotal factor in psychopathology
[35]. In addition, a systematic review evaluating pro-
inflammatory markers in almost 4,000 children and ado-
lescents with neuropsychiatric and neurodevelopmental
disorders, including ASD, identified preliminary evidence
of the role of inflammation in these conditions and an
association with a pro-inflammatory state [36]. Further-
more, growth in research into the role of inflammation has
led to the redefinition of many diseases, such as heart
disease, Alzheimer’s disease, type 1 diabetes, type 2 dia-
betes, and obesity, as inflammatory disorders [13]. A pos-
sible mechanism for the role of inflammation in these
disorders is the alteration of the structural and functional
integrity of the central nervous system (CNS) by cytokines,
thereby contributing to the pathology of neuro-inflamma-
tion and neuropsychological disorders.
Peripheral cytokine signals are thought to access the
brain through three pathways: humoral (with antibody
involvement), neural, and cellular [30]. These communi-
cation pathways involve at least five mechanisms: (1)
passage of cytokines through leaky regions of the blood-
brain barrier; (2) active transport via saturable cytokine-
specific transport molecules on brain endothelium; (3)
activation of endothelial cells, which release second mes-
sengers within the brain parenchyma; (4) transmission of
cytokine signals via afferent nerve fibers, including the
vagus; and (5) entry into the brain parenchyma of periph-
erally-activated monocytes which release cytokines.
Cytokines may influence behavior through effects on
neurotransmitter function, neuroendocrine activity, neuro-
genesis, and alterations to brain circuitry [30]. For exam-
ple, cytokines have been shown to increase the release and
decrease reuptake of the excitatory neurotransmitter glu-
tamate, which can result in the pathological process of
excitotoxicity [37]. This type of mechanism could support
a model for some types of ASD; the model postulates an
increased excitation/inhibition ratio in key neural systems,
such as sensory, mnemonic, social, and emotional systems
[38].
An alternate communication pathway has recently been
proposed based on the groundbreaking work by Louveau
and colleagues who identified functional lymphatic vessels
in the CNS that carry fluid and immune cells from the
cerebrospinal fluid, and in doing so discovered a pathway
for immune cells to exit the CNS [39]. While the anatomy
and functional importance of these pathways and systems
have yet to be characterized in humans, this work provides
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a new perspective on the possible etiology of neuroin-
flammatory and neurodegenerative conditions. These
findings also provide an impetus for further consideration
of the relationship between immune responses and behav-
iors in other conditions that are characterized by immune
system dysfunction, such as ASD.
An understanding of the pathways and mechanisms
through which the immune system affects behavior is pri-
marily based on findings in animal models. For example,
mice deficient in T cells have cognitive deficits [25].
Interestingly, an altered activation profile for T cells has
been identified in ASD, with these perturbations of T cell
function possibly modulating behavior and core features of
ASD [40]. Recently, social behavior as operationalized
within an animal model, has been shown to be influenced
by meningeal immunity [41]. Mice deficient in adaptive
immunity, specifically an absence of interferon IFN-c,
display both hyper-connectivity in the prefrontal cortex
(PFC) and significant social deficits. This is particularly
interesting, given that hyperactivity in the PFC in the
context of social stimuli is known to be a feature of social
impairment in ASD [42]. Filiano and colleagues demon-
strated that CNS neurons respond to IFN-c derived from
meningeal T cells, elevating tonic GABAergic inhibition
[41]. This process prevents aberrant hyper-excitability in
the PFC and restores social behaviors through IFN-c.
Previously, IFN-c released from T cells was thought to
predominantly stimulate and modulate immune responses
to infection. Interestingly, NK cells, recognized as major
producers of cytokines including IFN-c [12] in physio-
logical and pathological conditions, are dysfunctional in
ASD [43]. While a novel finding, the regulation of neural
activity and social behavior through IFN-c provides further
evidence for the interconnectedness of the immune system,
the nervous system, and behavior.
Immune System Deregulation in ASD
Evidence suggesting a pathophysiological relationship
between the immune system and ASD was first presented
over 40 years ago [44]. Subsequent research investigating
the complex relationship between the immune system and
ASD symptomatology has identified numerous potential
interactions and proposed associated mechanisms at both
the systemic and cellular levels [7, 45]. One of these areas
of research focuses on the prenatal period. Maternal
immune activation refers to the defensive response of the
mother’s immune system to an invading pathogen. A large
population-based study found that acute immune activation
caused by maternal viral infection during the first trimester
increases the risk of ASD in children [46]. Furthermore, a
recent meta-analysis of[40,000 ASD cases showed that
maternal infection during pregnancy is associated with an
increased risk of ASD in the offspring, with hospitalization
during infection heightening the risk [47]. Moderators of
this risk include the type of infectious agent, the timing of
infectious exposure, and the site of infection. A recent
review has proposed that maternal infection leads to the
release of pro-inflammatory cytokines and activation of
Th17 cells in the mother’s bloodstream and that the
immune status and genetic predisposition of the fetus
determine its vulnerability to maternal immune activation,
a process considered a disease primer [48]. Peripheral
cytokine profiles at birth, including elevated IL-1b and IL-
4, are associated with an ASD diagnosis later in childhood
and vary with ASD symptom severity [49]. Elevation of
IL-1b and IL-4 may reflect a prenatal immune challenge,
and an association with both ASD risk and cognitive
developmental outcomes suggests the possibility of a glo-
bal impact of early cytokine dysregulation [49]. Familial
autoimmunity has also been implicated in the pathogenesis
of ASD, with an increased risk of ASD in children with a
maternal history of rheumatoid arthritis and celiac disease,
and an increased risk of infantile autism has been identified
in children with a family history of type 1 diabetes [50].
Another area of focus on immune involvement in the
pathogenesis and maintenance of ASD is the postnatal
period. Altered cytokine profiles have been consistently
linked to ASD in children during this period [7]. In high-
functioning male children with ASD, the plasma levels of
IL-1b, IL-1 receptor antagonist (IL-1RA), IL-5, IL-8, IL-
12(p70), IL-13, and IL-17 are elevated relative to matched
controls [51]. IL-1b, a pro-inflammatory cytokine, acti-
vates neutrophils and macrophages to phagocytose invad-
ing pathogens [52]. IL-1RA inhibits the activities of IL-1b,
suggesting that the levels of IL-1RA might be a function of
a negative feedback regulator role in response to the ele-
vation of IL-1b [51]. IL-1b is involved in the production of
IL-17 [53] and IL-17 is a potent mediator of the production
of IL-8, a chemokine with important roles in the innate
immune response. IL-5 and IL-13 stimulate B cells to
secrete immunoglobulins including IgE, which is a medi-
ator of allergic inflammation. IL-12(p70) is a pro-inflam-
matory cytokine that enhances Th1 and NK cell responses
[54]. In addition to elevated expression of IL-1b, as iden-
tified by Suzuki and colleagues, IL-6, IL-12, TNF-a, and
IL-23 are also elevated in ASD compared to healthy con-
trols, suggesting a dysregulated immune response [55].
TNF-a is a central regulator of inflammation and is ele-
vated in the cerebrospinal fluid of children with ASD [56].
IL-6 is typically regarded as a pro-inflammatory cytokine
and has been identified as a cytokine the brain recognizes
as a molecular signal of sickness [28]. However, it also has
regenerative or anti-inflammatory activity, and is involved
in the regulation of metabolic and neural processes [57].
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Finally, a further example of immune abnormalities in the
postnatal period involves activation of the monocytic and
Th1 arm of the immune response, via increased IL-1RA
and increased IFN-c, respectively, and this has been found
in children with ASD [58].
Immune-mediated mechanisms have also been hypoth-
esized as reflecting a chronic state of specific cytokine
activation [59]. Immunocytochemical studies have identi-
fied marked activation of microglia and astroglia associated
with the increased production of two cytokines by neu-
roglia, macrophage chemoattractant protein (MCP)-1, and
TGF-b1 [59]. In addition, a unique profile of pro-inflam-
matory cytokines has been identified in cerebrospinal fluid
[59]. Another post-mortem study also demonstrated sig-
nificant increases in pro-inflammatory and Th1 cytokines
relative to matched controls [60]. Elevation of IL-6 in
ASD, both centrally and peripherally, has been frequently
reported [59–62]. In a mouse model with elevated IL-6 in
the brain, Wei and colleagues have shown that IL-6 can
modulate autism-like behaviors through impairments of
synapse formation, dendritic spine development, and neu-
ronal circuit balance [63]. Acute and chronic psychological
stress and alterations in sleep duration and quality, a
commonly reported comorbidity in ASD [64], increase the
concentrations of IL-6 [65]. This evidence for abnormal
cytokine profiles in ASD suggests that immune system
disturbances may be active and continuous contributors to
the presentation of ASD. It is this accumulation of evi-
dence that has acted as the catalyst for efforts to charac-
terize possible subgroups of ASD patients who present with
immune system abnormalities or dysfunction and altered
patterns of symptom presentation [9, 66].
Associations between changes in peripheral cytokine
expression and the severity of behavioral impairments and
associated symptoms have been identified in children with
ASD (Table 2). Reduced levels of the regulatory cytokine
TGF-b1 are associated with reduced adaptive behavior and
worsening behavioral symptoms [67, 68]. While TGF-b1 is
involved in cell growth and differentiation, organ devel-
opment, migration, and apoptosis, its major role is to
control inflammation. This negative correlation with
behavioral impairment suggests that there is an ongoing
inflammatory process in children with ASD who present
with worsening behavioral profiles [67]. Increased levels of
the chemokines MCP-1, RANTES (regulated on activation,
normal T cell expressed and secreted), and eotaxin are
associated with more impaired behaviors and adaptive
functioning [69]. Chemokines are expressed in the devel-
oping brain and regulate neuronal cell migration, prolifer-
ation, and differentiation. They are also involved in
communication between neurons and microglia [70]. Ele-
vated IL-1b and IL-6 have been associated with increased
stereotypical behaviors [62]. Dysregulation of IL-1b, a pro-
inflammatory cytokine expressed early in an immune
response, is implicated in impairments in memory and
learning [71]. IL-1b induces and inhibits neural progenitor
cell proliferation in the CNS, which can contribute to
region-specific deviant brain growth in ASD [72]. As
previously highlighted, IL-6 is elevated in most inflam-
matory states and has been implicated in a wide range of
conditions. Elevation of IL-8 and IL-12p40 is also associ-
ated with greater impairment of aberrant behaviors
including lethargy and stereotypy as measured by the
Aberrant Behavior Checklist (ABC) [62]. In addition, as
the expression of IL-8 decreases, cognitive and adaptive
ability improves [62]. IL-8 is a chemoattractant cytokine,
attracting and activating neutrophils in regions of inflam-
mation [73] and hence may contribute to the pathogenesis
of inflammatory diseases [74].
Other cellular markers of immune dysfunction identified
in children with ASD include significantly higher absolute
numbers of B cells and NK cells, and increased markers of
cellular activation compared to healthy controls [75]. These
findings suggest an immune response activation that leads
to an increased frequency of NK cells and activated B cells
and T cells. Increased levels of the IgG4 subclass have been
identified in children with ASD [76]. The IgG4 subclass has
features and biological function different from other sub-
classes of IgG, acting as a blocking antibody that binds
strongly to antibody receptors rather than a protective
antibody. A correlation between the severity of behavioral
measures and reduced levels of immunoglobulin has also
been found, suggesting suboptimal humoral function in
children with ASD [77]. Furthermore, an elevated preva-
lence of other immune-related comorbidities, including
autoimmune diseases, allergies, and psoriasis, has been
found in children with ASD compared to healthy controls
[6]. Overall, these relationships between immune dysfunc-
tion and behavioral symptoms associated with an ASD
presentation suggest an ongoing relationship impacting the
severity of the condition in children with an ASD diagnosis.
Altered Cytokine Profiles as Potential Biomarkers
in ASD
To facilitate improved communication about measure-
ments of disease and treatment effects, an expert working
group convened by the National Institutes of Health
Director’s Initiative on Biomarkers and Surrogate End-
points (USA) proposed the following definition of a bio-
logical marker or biomarker: a characteristic that is
objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention [78].
Additional applications of biomarkers have been proposed,
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such as use as a diagnostic tool for the identification of
those patients with a disease or abnormal condition, and for
the prediction and monitoring of the clinical response to an
intervention. Specifically, with respect to using biomarkers
to guide better treatment of schizophrenia and other psy-
chotic disorders, Banati and Hickie have proposed clini-
cally useful properties of biomarkers, including
diagnostically non-specific, quantitative, longitudinal,
plausibly linked to underlying pathophysiology, and pre-
dictive of risk of impairment [79]. They also highlight the
clinical importance of the role of biomarkers in guiding
treatment selection, and demonstrating a correlation
between active interventions and the short-term clinical
response.
Numerous biomarkers have been proposed for ASD,
including biochemical, morphological, immunological,
hormonal, neurophysiological, neuroanatomical, and neu-
ropsychological markers [80]. A recent clinical trial in
ASD involving an immunomodulatory pharmacological
intervention demonstrates a correlation between an active
intervention and a relevant short-term clinical response.
Greater improvement in symptoms of irritability, hyper-
activity, stereotypic behavior, social withdrawal, and
inappropriate speech was achieved when risperidone was
used adjunctively with pentoxifylline, an immune-modu-
lating drug and pro-inflammatory cytokine inhibitor [81].
Furthermore, another adjunct treatment trial in children
with ASD using risperidone and pioglitazone showed
reductions in the severity of symptoms of irritability, social
withdrawal, and hyperactivity in the adjunct treatment
group compared to the risperidone-only group, indicating
positive effects of pioglitazone [82]. Pioglitazone is a
Table 2 Cytokines and associations with severity of autism-related symptoms.
Cytokine n (ASD) Medium Measures Finding Study
TGF-b1 75 Plasma ABC, VABS Reduced levels associated with reduced adaptive behavior and worsened
behavioral symptoms including stereotypy, irritability, and hyperactivity
Ashwood
et al. [67]
Eotaxin 80 Plasma ABC, MSEL,
VABS




Increased levels associated with greater impairments in visual reception, fine
motor skills, and receptive and expressive language (MSEL)
Increased levels associated with greater impairments in communication, daily
living skills, socialization, and motor skills (VABS)
MCP-1 80 Plasma ABC, MSEL,
VABS
Increased levels associated with greater impairments in visual reception, fine
motor skills and expressive language (MSEL)
Ashwood
et al. [69]
Increased levels associated with greater impairments in daily living skills
(VABS)
RANTES 80 Plasma ABC, MSEL,
VABS




Increased levels associated with greater impairments in visual reception, fine
motor skills, and expressive language (MSEL)
Increased levels associated with greater impairments in communication and
socialization (VABS)
IL-1b 97 Plasma ADI-R, ABC,
MSEL, VABS
Increased levels associated with increased stereotypy (ABC) Ashwood
et al. [62]
IL-4 97 Plasma ADI-R, ABC,
MSEL, VABS




IL-6 97 Plasma ADI-R, ABC,
MSEL, VABS
Increased levels associated with increased stereotypy (ABC) Ashwood
et al. [62]
IL-8 97 Plasma ADI-R, ABC,
MSEL, VABS




Decreased levels associated with improved visual reception, receptive
language, and expressive language (MSEL)
Decreased levels associated with improved daily living skills (VABS)
IL-12p40 97 Plasma ADI-R, ABC,
MSEL, VABS
Increased levels associated with increased stereotypy and lethargy (ABC) Ashwood
et al. [62]
TGF-b1 30 Plasma CARS Reduced levels associated with increasing severity El Gohary
et al. [68]
ABC, Aberrant Behavior Checklist; ADI-R, Autism Diagnostic Interview—Revised; IL, interleukin; MCP-1, monocyte chemotactic protein-1;
MSEL, Mullen Scales of Early Learning; RANTES, regulated on activation, normal T cell expressed and secreted; TGF-b1, transforming growth
factor-b1; VABS, Vineland Adaptive Behavior Scales; WAIS-R, Wescheler Adult Intelligence Scale-Revised.
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peroxisome proliferator-activated receptor, which inhibits
the production of pro-inflammatory cytokines and
chemokines by microglia [83, 84]. Furthermore, risperi-
done was found to be more effective when given adjunc-
tively with celecoxib, a nonsteroidal anti-inflammatory
drug, with significant improvements in the irritability,
social withdrawal, and stereotypy subscales of the ABC
[85]. However, in a recent open-label study of risperidone
treatment for children and adolescents with ASD, the
plasma levels of eotaxin and MCP-1 showed statistically
significant decreases after treatment, although these chan-
ges were not significantly associated with changes in
severity measures [86]. Eotaxin and MCP-1 are pro-
inflammatory and are elevated in brain specimens from
patients with ASD [59]. Overall, the results of these trials
suggest that treating immune-related symptoms may con-
tribute to behavioral changes in ASD.
The clinical trials of immune-modulating agents, taken
together with previous examples of immune system per-
turbations in children with ASD, suggest that cytokines are
worthy of consideration as potential biomarkers of a sub-
group of individuals with an ASD diagnosis and more
severe behavioral outcomes. However, the validity of
peripheral sampling of blood cells as a relevant biomarker
and as a surrogate for a CNS sample is still debated. Given
that peripheral blood cells comprise the major cellular
components of the immune system, they could be consid-
ered suitable for the assessment of immune-related markers
[87]. In addition, accessibility and speed of sampling for
regular assessments and analysis of peripheral blood sam-
pling are significant advantages over, for example, cere-
brospinal fluid sampling and brain imaging.
A National Research Council (USA) report on precision
medicine, which is the tailoring of medical treatment to the
individual characteristics of each patient, highlights a
critical need for the deconstruction of current diagnostic
groups using biomarkers to help identify the subgroups for
which treatment is highly effective [88, 89]. In addition to
physical signs and symptoms, it is recommended that
conditions should also be defined by their underlying
molecular causes and other factors, which would represent
an emergence of a new taxonomy based on biomedical
research and an extensive patient data network. A data
network would be needed to integrate current research on
the molecular composition of conditions with clinical data
on individual patients in an effort to drive precision med-
icine. Precision medicine also refers to the classification of
individuals into subpopulations that differ in their suscep-
tibility to a particular condition in the biology and/or
prognosis of those conditions they may develop, or in their
response to a specific treatment [89]. Similarly, the long-
term aim of the Research Domain Criteria (RDoC) project
of the National Institute of Mental Health (USA) is
precision medicine for psychiatry through the adoption of a
diagnostic system based on a comprehensive understanding
of the biological and psychosocial bases of conditions,
unhindered by the limitations of diagnostic categories [88].
A robust biological system is one that maintains its state
and functions against external and internal perturbations
[90]. It is possible that a robust immune system is protective
and that while the mechanisms leading to abnormal function
have yet to be established, it is tempting to consider that a
regulated and functional immune system, both pre- and
postnatally, is a prerequisite for a normal functioning brain
[91]. Consistent with the RDoC agenda, the non-specific
association found between inflammation and neuropsychi-
atric disorders, including ASD, and the identification of
common reliable inflammatory markers across those dif-
ferent disorders warrant further investigations to determine
if these processes play a role in the etiology of symptom
dimensions or symptom domains that overlap or are shared
by different conditions [35]. A diagnosis of ASD continues
to be behaviorally defined. However, the body of research
and accumulating evidence with respect to immune system
perturbations in ASD suggest that a broader approach
should be taken in order to understand biological systems as
they pertain to ASD and associated behaviors.
Conclusion
The hallmark heterogeneity of ASD is a key reason for the
focus of researchers on the identification of potential bio-
logical measures as a means of describing subsets within
ASD, and thereby facilitating the targeting of more indi-
vidualized therapies. Previously discussed cytokine aber-
rations in ASD have highlighted a possible relationship
between cytokine aberration and ASD. Altered cytokine
levels may facilitate the identification of ASD subtypes that
share similar traits and profiles, as well as provide bio-
logical markers that facilitate monitoring of the benefits of
active treatments over the time-course of clinical trials.
Biological markers, as objective measures of the response
to treatment in clinical trials, will assist with the identifi-
cation of efficacious interventions. Furthermore, the iden-
tification of objective markers of a pathological state
related to a subgroup in ASDs may assist in reducing the
heterogeneity of participants in clinical trials, and this may
lead to the identification of more targeted treatments for
autism-related symptoms.
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